Targeting HMGB1 Increased the Sensitivity of MM Cells to Chemotherapy

Xing Guo,Donghua He,Jing Chen,Li Yang,Yi Li,Qingxiao Chen,Jingsong He,Yang,Enfan Zhang,Wenjun Wu,Xiaoyan Han,Gaofeng Zheng,Yi Zhao,He Huang,Zhen Cai
DOI: https://doi.org/10.1182/blood.v124.21.5703.5703
IF: 20.3
2014-01-01
Blood
Abstract:Background :Multiple myeloma (MM) is an malignant disease of clonal plasma cell hyperplasia, which incidence is increasing in recent years. Chemotherapy is the main method to treat MM, but because of drug resistance, MM is still an incrurable disease. High-mobility group box 1 protein (HMGB1) is a chromatin associated nuclear protein, which participated in DNA damage repair , rearrangement, and it also as an extracellular damage associated molecular pattern molecule(DAMP) involved in inflammation, neoplastic progression, angiogenesis, invasion and metastasiss and drug resistance of kinds of tumor cells. There’s no research about the role of HMGB1 in multiple myeloma before.
What problem does this paper attempt to address?